Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597334 | 0.88 | P2RX3 (0.33) | LMNAENPP2ALDH1A1MAPT | |
| SCHEMBL14439866 | 0.84 | L3MBTL1 (0.38) | POLBCCR5LMNAALDH1A1MAPT | |
| SCHEMBL5852655 | 0.83 | P2RX3 (0.33) | LMNAENPP2ALDH1A1MAPT | |
| Capravirine SCHEMBL4656686 | 0.82 | PIM1 (0.35) | LMNAENPP2ALDH1A1MAPT | |
| Capravirine SCHEMBL40347 | 0.82 | PIM1 (0.35) | LMNAENPP2ALDH1A1MAPT | |
| SCHEMBL6161001 | 0.82 | ENPP2 (0.35) | LMNAENPP2ALDH1A1 | |
| SCHEMBL6167205 | 0.81 | ENPP2 (0.34) | LMNAENPP2ALDH1A1 | |
| SCHEMBL6961504 | 0.81 | ENPP2 (0.35) | LMNAENPP2ALDH1A1 | |
| SCHEMBL6961345 | 0.81 | L3MBTL1 (0.39) | POLBALDH1A1 | |
| SCHEMBL6962314 | 0.79 | L3MBTL1 (0.36) | POLBCCR5LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462608-B2 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1620445-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| EP-1575486-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | GILEAD SCIENCES, INC. | 2005-09-08 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1501841-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004096818-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128692-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | HTR2A 4669/4885POLB 16/4885MMP13 1707/4885 |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | HTR2A 4812/4885POLB 861/4885MMP13 1606/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | HTR2A 4812/4885POLB 861/4885MMP13 1606/4885 |
| US-20050197320-A1 | Non nucleoside reverse transcriptase inhibitors | TYMP, PNP, ITPA | HTR2A 4669/4885POLB 16/4885MMP13 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.